Meeting
2022 ASCO Genitourinary Cancers Symposium
SWOG S1314: A randomized phase II study of co-expression extrapolation (COXEN) with neoadjuvant chemotherapy for localized, muscle-invasive bladder cancer with overall survival follow up.
Authors
Thomas W. Flaig
University of Colorado Anschutz Medical Campus, Aurora, CO
Thomas W. Flaig , Catherine Tangen , Siamak Daneshmand , Ajjai Shivaram Alva , M. Scott Lucia , David McConkey , Dan Theodorescu , Amir Goldkorn , Matthew I. Milowsky , Rick Bangs , Gary R. MacVicar , Bruno R. Bastos , Jared Fowles , Daniel Gustafson , Melissa Plets , Ian Murchie Thompson Jr., Seth P. Lerner
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Urothelial Carcinoma
Track
Urothelial Carcinoma
Sub Track
Translational Research, Tumor Biology, Biomarkers, and Pathology
Clinical Trial Registration Number
NCT02177695
Citation
J Clin Oncol 40, 2022 (suppl 6; abstr 536)
DOI
10.1200/JCO.2022.40.6_suppl.536
Abstract #
536
Poster Bd #
H8
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Association of molecular subtypes with pathologic response in a phase II study of co-expression extrapolation (COXEN) with neoadjuvant chemotherapy (NAC) for localized, muscle-invasive bladder cancer (SWOG S1314; NCT02177695).
First Author: Seth P. Lerner
Poster
2023 ASCO Genitourinary Cancers Symposium
FDG PET-CT imaging in assessing interim response to neoadjuvant cisplatin-based chemotherapy (NAC) in muscle invasive bladder cancer (MIBC): A prospective study.
First Author: Srikala S. Sridhar
Poster
2019 ASCO Annual Meeting
Defects in DNA repair genes and long-term survival in cisplatin-based neoadjuvant chemotherapy for muscle invasive bladder cancer (MIBC).
First Author: Benjamin Miron
Poster
2019 Genitourinary Cancers Symposium
Comparing clinical outcomes between patients with urothelial carcinoma who treated neoadjuvant chemotherapy by gemcitabine-cisplatin and dose-dense MVAC.
First Author: Yongjune Lee